Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Scicinski

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
Oncotarget|December 15, 2015
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activityHongjuan Zhao, Shoucheng Ning, Jan Scicinski, et al.
Discovery Medicine|May 28, 2016
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cellsBryan Oronsky, Jan Scicinski, Tony Reid, et al.
Malaria Journal|May 29, 2015
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malariaOzlem Yalcin, Bryan Oronsky, Leonardo J M Carvalho, et al.
Respiratory Medicine Case Reports|June 23, 2016
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLCCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Discovery Medicine|April 27, 2016
Rockets, radiosensitizers, and RRx-001: an origin story part IBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Clinical Epigenetics|February 3, 2017
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicryHongjuan Zhao, Shoucheng Ning, Rosalie Nolley, et al.
Investigational New Drugs|February 5, 2016
RRx-001, A novel dinitroazetidine radiosensitizerBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Plos One|July 10, 2014
The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditionsMarcel H Fens, Sandra K Larkin, Bryan Oronsky, et al.
Medical Oncology (Northwood, London, England)|May 28, 2016
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?Pedro Cabrales, Jan Scicinski, Tony Reid, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Oncotarget|January 28, 2016
Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapyBryan Oronsky, Corey Carter, Anna Scicinska, et al.
Oncotarget|December 15, 2015
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activityHongjuan Zhao, Shoucheng Ning, Jan Scicinski, et al.
Discovery Medicine|May 28, 2016
RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cellsBryan Oronsky, Jan Scicinski, Tony Reid, et al.
Malaria Journal|May 29, 2015
From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malariaOzlem Yalcin, Bryan Oronsky, Leonardo J M Carvalho, et al.
Respiratory Medicine Case Reports|June 23, 2016
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLCCorey A Carter, Bryan Oronsky, Scott Caroen, et al.
Discovery Medicine|April 27, 2016
Rockets, radiosensitizers, and RRx-001: an origin story part IBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Clinical Epigenetics|February 3, 2017
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicryHongjuan Zhao, Shoucheng Ning, Rosalie Nolley, et al.
Investigational New Drugs|February 5, 2016
RRx-001, A novel dinitroazetidine radiosensitizerBryan Oronsky, Jan Scicinski, Shoucheng Ning, et al.
Plos One|July 10, 2014
The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditionsMarcel H Fens, Sandra K Larkin, Bryan Oronsky, et al.
Medical Oncology (Northwood, London, England)|May 28, 2016
A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?Pedro Cabrales, Jan Scicinski, Tony Reid, et al.
Pageof 5